Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs Axsome Therapeutics, Inc.

SG&A Expenses: A Tale of Two Biotech Giants

In the ever-evolving landscape of biotechnology, understanding the financial dynamics of industry leaders is crucial. Gilead Sciences, Inc. and Axsome Therapeutics, Inc. present a fascinating study in contrasts when it comes to Selling, General, and Administrative (SG&A) expenses. Over the past decade, Gilead's SG&A expenses have consistently dwarfed those of Axsome, reflecting its established market presence and expansive operations. In 2023, Gilead's SG&A expenses reached approximately $6.09 billion, a 104% increase from 2014. Meanwhile, Axsome, a rising star in the biotech sector, saw its SG&A expenses grow exponentially, from a modest $1.39 million in 2014 to $323 million in 2023, marking a staggering increase of over 23,000%. This dramatic rise underscores Axsome's aggressive expansion and investment in market penetration. As these companies continue to innovate, their financial strategies offer valuable insights into their growth trajectories and market strategies.